The authors concluded that DNMT3A mutations act as an unfavorable prognostic factor in AML patients with normal cytogenetics and allogeneic HSCT improves survival in DNMT3A mutation-positive AML patients. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.